RxDoctor Payments Data

Benjamin Tu, MD

Internal Medicine · Bethel Park, PANPI 1053520361

Payments from drug & device makers

$21,912in general payments, 2019–2025

Across 1,295 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • GSK$2K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • plus $9K from 50 others

What the payments were for

  • Food & beverage$21,884100%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$21,912 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$38,401
Medicare patients
115
Services billed
579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$120,899
JardianceEmpagliflozin134$110,391
MounjaroTirzepatide92$108,981
EliquisApixaban82$90,816
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$70,363
TrulicityDulaglutide27$43,234
XifaxanRifaximin13$40,939
FarxigaDapagliflozin Propanediol49$38,895
RybelsusSemaglutide38$36,467
XareltoRivaroxaban31$27,674
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$27,377
TradjentaLinagliptin31$26,826
LinzessLinaclotide38$24,352
WegovySemaglutide17$22,773
Repatha SureclickEvolocumab29$19,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$2,337$180,140137 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto$494$155,706200 claims
Lilly USA, LLCMounjaro, Trulicity$1,887$152,215119 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,606$111,814159 claims
PfizerEliquis$1,112$90,81682 claims
AstraZenecaFarxiga, Breztri Aerosphere$840$46,80362 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$409$40,93913 claims
Johnson & JohnsonXarelto$1,480$27,67431 claims
AbbVieLinzess$4,643$24,35238 claims
AmgenProlia$1,065$18,76811 claims
NovartisEntresto$280$16,03816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Bethel Park

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →